Immunomodulatory effects of lenvatinib in patients with advanced thyroid cancer.

Cancer Immunol Immunother · 2025 · PMC12717327 · PMID 41417071

Europe PMC DOI

hedged sentence

0.0986

closest p · 2.0× alpha

0.0986

boldest claim

The sentences

showed a trendp = 0.0986so close (0.05 < p ≤ 0.1)

Furthermore, PBMCs of lenvatinib-treated patients were associated with a higher production capacity of IFN-γ and showed a trend toward an increased production of IL-17 ( p = 0.0986) (Fig. 3 C).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.